TME PHARMA NV (ALTME.PA) Fundamental Analysis & Valuation

EPA:ALTME • NL0015000YE1

Current stock price

0.079 EUR
0 (-1.25%)
Last:

This ALTME.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ALTME.PA Profitability Analysis

1.1 Basic Checks

  • ALTME had negative earnings in the past year.
  • In the past year ALTME has reported a negative cash flow from operations.
  • ALTME had negative earnings in each of the past 5 years.
  • In the past 5 years ALTME always reported negative operating cash flow.
ALTME.PA Yearly Net Income VS EBIT VS OCF VS FCFALTME.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

  • ALTME has a worse Return On Assets (-199.56%) than 91.67% of its industry peers.
Industry RankSector Rank
ROA -199.56%
ROE N/A
ROIC N/A
ROA(3y)-242.38%
ROA(5y)-194.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALTME.PA Yearly ROA, ROE, ROICALTME.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K 1.5K 2K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ALTME so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALTME.PA Yearly Profit, Operating, Gross MarginsALTME.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. ALTME.PA Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for ALTME has been increased compared to 1 year ago.
  • The number of shares outstanding for ALTME has been increased compared to 5 years ago.
  • ALTME has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ALTME.PA Yearly Shares OutstandingALTME.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ALTME.PA Yearly Total Debt VS Total AssetsALTME.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

  • ALTME has an Altman-Z score of -127.51. This is a bad value and indicates that ALTME is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -127.51, ALTME is doing worse than 94.44% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -127.51
ROIC/WACCN/A
WACCN/A
ALTME.PA Yearly LT Debt VS Equity VS FCFALTME.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

2.3 Liquidity

  • A Current Ratio of 0.79 indicates that ALTME may have some problems paying its short term obligations.
  • The Current ratio of ALTME (0.79) is worse than 77.78% of its industry peers.
  • A Quick Ratio of 0.79 indicates that ALTME may have some problems paying its short term obligations.
  • ALTME has a Quick ratio of 0.79. This is in the lower half of the industry: ALTME underperforms 76.39% of its industry peers.
Industry RankSector Rank
Current Ratio 0.79
Quick Ratio 0.79
ALTME.PA Yearly Current Assets VS Current LiabilitesALTME.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. ALTME.PA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 86.56% over the past year.
EPS 1Y (TTM)86.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.23%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • ALTME is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 53.46% yearly.
  • Based on estimates for the next years, ALTME will show a very negative growth in Revenue. The Revenue will decrease by -25.99% on average per year.
EPS Next Y89.47%
EPS Next 2Y21.4%
EPS Next 3Y53.46%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A

3.3 Evolution

ALTME.PA Yearly Revenue VS EstimatesALTME.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2024 100K 200K 300K
ALTME.PA Yearly EPS VS EstimatesALTME.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -200 -400 -600

More info and screens

Find the best growth stocksShow best growing peers

1

4. ALTME.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • ALTME reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALTME. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALTME.PA Price Earnings VS Forward Price EarningsALTME.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALTME.PA Per share dataALTME.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.05 -0.1 -0.15

4.3 Compensation for Growth

  • ALTME's earnings are expected to grow with 53.46% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.4%
EPS Next 3Y53.46%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ALTME.PA Dividend Analysis

5.1 Amount

  • No dividends for ALTME!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALTME.PA Fundamentals: All Metrics, Ratios and Statistics

TME PHARMA NV

EPA:ALTME (4/28/2026, 7:00:00 PM)

0.079

0 (-1.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength37.16
Industry Growth78
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners3.98%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap7.44M
Revenue(TTM)27.00K
Net Income(TTM)-4.58M
Analysts84.44
Price Target0.11 (39.24%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 275.59
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.08
EYN/A
EPS(NY)-0.15
Fwd EYN/A
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS0
BVpS-0.01
TBVpS-0.01
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -199.56%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-242.38%
ROA(5y)-194.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 63.16%
Cap/Sales 44.44%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.79
Quick Ratio 0.79
Altman-Z -127.51
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)18.84%
Cap/Depr(5y)27.5%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)86.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.23%
EPS Next Y89.47%
EPS Next 2Y21.4%
EPS Next 3Y53.46%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
EBIT growth 1Y18.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year83.64%
EBIT Next 3Y129.06%
EBIT Next 5YN/A
FCF growth 1Y50.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.78%
OCF growth 3YN/A
OCF growth 5YN/A

TME PHARMA NV / ALTME.PA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of TME PHARMA NV (ALTME.PA) stock?

ChartMill assigns a fundamental rating of 0 / 10 to ALTME.PA.


What is the valuation status for ALTME stock?

ChartMill assigns a valuation rating of 1 / 10 to TME PHARMA NV (ALTME.PA). This can be considered as Overvalued.


How profitable is TME PHARMA NV (ALTME.PA) stock?

TME PHARMA NV (ALTME.PA) has a profitability rating of 0 / 10.


Can you provide the financial health for ALTME stock?

The financial health rating of TME PHARMA NV (ALTME.PA) is 0 / 10.